Weeks after Sanofi flop, Roche's rival breast cancer drug flunks phase 2 test Phase 2 deja vu for gossamer bio after ulcerative colitis med flops Black Diamond runs into rocky terrain, trims 30% of workforce and cuts precision oncology program Sponsored: Using Knowledge Graphs to Drive Drug Discovery Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine war Clean safety profiles and complete responses: Nkarta releases early-stage data for 2 cancer candidates Reprogramming a new type of T cell to go after cancers with less side effects, longer impact Toronto researchers say ‘double negative’, off-the-shelf CAR-T treatment could bolster cell therapy The top advertisers in Big Pharma Here's why some systems say they're comfortable relaxing hospital mask requirements Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor Roche drinks in COVID test sale gains but preps for the well to run dry Gilead touts analysis showing COVID antiviral Veklury performs best when given early in illness Featured Story | By Nick Paul Taylor Chalk up another setback to the oral SERDs. In the wake of data that sank Radius Health's stock and the failure of Sanofi’s prospect, Roche has revealed giredestrant missed the mark in a midphase breast cancer trial, raising doubts about the drug ahead of further data drops. read more |
| |
|---|
|
| | Harness the power of eCOA in your next trial Keep patients at the center of care while increasing efficiencies, data integrity and regulatory compliance. IQVIA’s leaders will help you deploy strategic eCOA tools, maximize patient needs and acquire real-time insights that demonstrate results. Learn more. |
Top Stories By Max Bayer Gossamer bio is headed back to the drawing board after its ulcerative colitis med flopped in phase 2, prompting the company to end open-label and treat-through extensions of the trial. The company did not specifically say whether or not it would continue with the program. read more By Annalee Armstrong Black Diamond Therapeutics is closing down at least one run at a precision oncology med after getting a glimpse of the rocky terrain ahead and cutting 30% of staff in the process. read more Sponsored By: QIAGEN Digital Insights Biomedical knowledge graphs can power many different application in drug discovery. Learn which key feature you should look for and why. read more By James Waldron When it comes to clinical trials, things rarely go to plan. Just ask Roche, which revealed today that it has pushed back the regulatory timeline for its Duchenne muscular dystrophy (DMD) treatment by a year. In addition, the Big Pharma noted that the conflict in Ukraine has thrown its multiple sclerosis trials into disarray. read more By Gabrielle Masson Following a blockbuster IPO and partnership with CRISPR, clinical-stage biotech Nkarta has released some of the first data for its two leading engineered natural killer (NK) cell programs to treat cancer. read more By Sophia Sorensen Immunotherapy is one of the more appealing and effective kinds of cancer treatment but is still fairly limited in the kinds of cancer it can be used for. Researchers at the Sloan Kettering Institute discovered the workings of a new kind of immune cell that could expand the reach of immunotherapy treatments to a much wider pool of patients. read more By Max Bayer A new study from a team of researchers in Toronto bolsters support for a novel "off-the-shelf" CAR-T treatment. The scientists found that "double negative" allogenic CAR-T cells were able to fight two types of cancers in a mouse model without the cells attacking the host's body. read more By Ben Adams The pandemic had a major effect on how pharma spent its marketing cash: While spending on direct-to-consumer branded drug ads remained flat in 2021, unbranded campaigns went through the roof. read more By Dave Muoio Houston Methodist and UnityPoint Health are among those letting staff and visitors cut back on masking outside clinical areas. With constant surveillance, they say the policy offers much-needed relief to staff members grappling with pandemic burnout. read more By Annalee Armstrong Ardelyx's Hail Mary attempt to save the FDA application for its kidney drug seems to have worked, as the agency has granted the struggling biotech a hearing for tenapanor. read more By Conor Hale Omicron’s surge in January drove Roche’s diagnostics sales to new highs in the first quarter of this year, as high demand for rapid COVID-19 tests joined forces with the momentum in the division’s base businesses. read more By Kevin Dunleavy During the European Congress of Clinical Microbiology & Infectious Diseases, Gilead Sciences presented data that showed its COVID-19 antiviral Veklury performs better the earlier it is provided in both patients with severe and mild-to-moderate cases of the virus. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 